rbn-2397
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2019 (NCT04053673)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
TIPARP inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05127590 | Phase 1/Phase 2 (Phase 2) | Nov 19, 2021 | Ribon Therapeutics, Inc., Tennessee Oncology, PLLC |
| NCT04053673 | Phase 1 | Aug 1, 2019 | Ribon Therapeutics, Inc., Tennessee Oncology, PLLC |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ribon Therapeutics, Inc. | For profit | 2 | 2 | 2 | 2019 |
| Tennessee Oncology, PLLC | Academic/Hospital | 2 | 0 | 2 | 2019 |
2 organizations
Page 1 / 1